May 16, 2025

FDA Clears First Blood Test for Alzheimer’s

The FDA has cleared the first blood-based test to aid in diagnosing Alzheimer’s disease, offering a less invasive alternative to positron emission tomography scans and cerebrospinal fluid testing for cognitively impaired patients.

Conexiant

May 16, 2025

FDA Approves PD-1–Targeted Monoclonal Antibody for SCAC

The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.

Conexiant

May 16, 2025

Delandistrogene Moxeparvovec: Efficacy Evidence Questioned

The AAN Guidelines Subcommittee review finds delandistrogene moxeparvovec for DMD failed to meet primary functional outcomes despite FDA approval.

Conexiant

May 15, 2025

Assistant Professor Salary Gaps Persist Nationwide

Persistent salary disparities by gender, race, and ethnicity were identified among more than 45,000 U.S. assistant professors, with underrepresented in medicine women learning the least across all specialties.

Conexiant

May 15, 2025

Chikungunya Vaccine Linked to Adverse Events

The FDA and CDC have paused use of the Ixchiq chikungunya vaccine in adults aged 60 and older due to reports of serious postmarketing adverse events.

Conexiant

May 07, 2025

Dr. Vinay Prasad Shakes Up FDA Leadership

The FDA has appointed Vinay Prasad as its new vaccine chief, shaking up biotech stocks and signaling potential shifts in drug approvals.

Reuters

May 06, 2025

Anemia Linked to Hidden Heart Strain in RA

A new study found that 1 in 3 rheumatoid arthritis patients with normal heart function on standard tests had hidden heart strain detectable only through advanced imaging, with anemia emerging as the strongest predictor.

Conexiant

May 06, 2025

Combo Therapy Shows Repigmentation Gains in Vitiligo

Ritlecitinib alone or with nbUVB therapy led to significant improvements in skin repigmentation among vitiligo patients, with more pronounced effects seen when both treatments were combined, according to a new phase 2b study.

Conexiant

May 05, 2025

Ustekinumab Biosimilar Receives Interchangeability Approval

Selarsdi (ustekinumab-aekn) was approved by the FDA as an interchangeable biosimilar to Stelara (ustekinumab) for all approved indications, including psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

Conexiant